Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ling-Ling Hwang

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Frontiers in Cellular Neuroscience|August 26, 2022
Electroacupuncture improves TBI dysfunction by targeting HDAC overexpression and BDNF-associated Akt/GSK-3β signalingShih-Ya Hung, Hsin-Yi Chung, Sih-Ting Luo, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2010
Intravenous paclitaxel against metastasis of human gastric tumors of diffuse typeTsung-Fan Tuan, Meng-Li Tsai, Kai-Chia Yeh, et al.
Anticancer Research|August 5, 2010
Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075Ching-Ping Chen, Chih-Bo Hu, Kai-Chia Yeh, et al.
Cancer Science|November 3, 2010
BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activitiesChih-Bo Hu, Ching-Ping Chen, Teng-Kuang Yeh, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Frontiers in Cellular Neuroscience|August 26, 2022
Electroacupuncture improves TBI dysfunction by targeting HDAC overexpression and BDNF-associated Akt/GSK-3β signalingShih-Ya Hung, Hsin-Yi Chung, Sih-Ting Luo, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2010
Intravenous paclitaxel against metastasis of human gastric tumors of diffuse typeTsung-Fan Tuan, Meng-Li Tsai, Kai-Chia Yeh, et al.
Anticancer Research|August 5, 2010
Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075Ching-Ping Chen, Chih-Bo Hu, Kai-Chia Yeh, et al.
Cancer Science|November 3, 2010
BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activitiesChih-Bo Hu, Ching-Ping Chen, Teng-Kuang Yeh, et al.
Pageof 4